This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding the launch of AirDuo™ RespiClick® and its Authorized Generic, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:
Research has shown that the complications associated with type 2 diabetes often begin to develop well before the disease is diagnosed. Fifty percent of people found to have type 2 diabetes are already suffering from complications. Microvascular and macrovascular complications, such as retinopathy (eye disease), nephropathy (kidney disease), neuropathy (nervous system disease) and large vessel disease are all a consequence of poor blood sugar control, which may be worsened by weight excess, high blood pressure, smoking, and high cholesterol levels.